p53 and p16/p19 Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells.

Titlep53 and p16/p19 Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells.
Publication TypeJournal Article
Year of Publication2016
AuthorsAzzopardi S, Pang S, Klimstra DS, Du Y-CNancy
JournalNeoplasia
Volume18
Issue10
Pagination610-617
Date Published2016 Oct
ISSN1476-5586
KeywordsAnimals, Cell Transformation, Neoplastic, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase Inhibitor p19, Disease Models, Animal, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Mice, Mice, Transgenic, Neoplasm Metastasis, Neoplastic Stem Cells, Neuroendocrine Tumors, Pancreatic Neoplasms, Phenotype, Prognosis, Tumor Burden, Tumor Suppressor Protein p53
Abstract

In human studies and mouse models, the contributions of p53 and p16/p19 loss are well established in pancreatic ductal adenocarcinoma (PDAC). Although loss of functional p53 pathway and loss of Ink4a/Arf in human pancreatic acinar cell carcinoma (PACC) and pancreatic neuroendocrine tumor (PanNET) are identified, their direct roles in tumorigenesis of PACC and PanNET remain to be determined. Using transgenic mouse models expressing the viral oncogene polyoma middle T antigen (PyMT), we demonstrate that p53 loss in pancreatic Pdx1+ progenitor cells results in aggressive PACC, whereas Ink4a/Arf loss results in PanNETs. Concurrent loss of p53 and Ink4a/Arf resembles loss of p53 alone, suggesting that Ink4a/Arf loss has no additive effect to PACC progression. Our results show that specific tumor suppressor genotypes provocatively influence the tumor biological phenotypes in pancreatic progenitor cells. Additionally, in a mouse model of β-cell hyperplasia, we demonstrate that p53 and Ink4a/Arf play cooperative roles in constraining the progression of PanNETs.

DOI10.1016/j.neo.2016.08.003
Alternate JournalNeoplasia
PubMed ID27664376
PubMed Central IDPMC5035259
Grant ListP30 CA008748 / CA / NCI NIH HHS / United States
R21 CA173348 / CA / NCI NIH HHS / United States
U01 DK072473 / DK / NIDDK NIH HHS / United States